Zafgen to Announce First Quarter 2019 Financial Results
May 02 2019 - 4:30PM
Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical
company leveraging its proprietary knowledge of MetAP2 systems
biology to develop novel therapies for patients affected by a range
of metabolic diseases, announced today that it will announce
financial results for the first quarter ended on March 31, 2019
after the close of the U.S. financial markets on Thursday, May 9,
2019.
As Zafgen is currently in the regulatory process related to the
clinical hold for ZGN-1061, the Company has elected not to host a
quarterly call. An update on ZGN-1061 is still anticipated in Q2
2019.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical
company leveraging its proprietary MetAP2 biology platform to
develop novel therapies for patients affected by complex metabolic
diseases. Zafgen has pioneered the study of MetAP2 inhibitors in
both common and rare metabolic disorders. Learn more at
www.zafgen.com.
Media/Investor Relations Contacts:Zafgen, Inc.
Patricia Allen Chief Financial Officer 617-648-9792
MediaKrystle GibbsTen Bridge Communications
krystle@tenbridgecommunications.com 508-479-6358
InvestorsJohn
WoolfordWestwickejohn.woolford@westwicke.com443-213-0506
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Sep 2023 to Sep 2024